SCHEMBL1451027

SCHEMBL1451027

Cn1c(=O)ccc2[c]cccc21

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BRPF1 P55201 7/20 0.50
BRD4 O60885 3/20 0.50
BRD9 Q9H8M2 3/20 0.50
CA12 O43570 1/20 0.50
CA9 Q16790 1/20 0.50
KAT2B Q92831 1/20 0.50
KDM4E B2RXH2 2/20 0.38
NQO2 P16083 1/20 0.38
HSD17B10 Q99714 2/20 0.35
ALDH1A1 P00352 2/20 0.32
CYP1A2 P05177 1/20 0.32
HPGD P15428 1/20 0.32
BLM P54132 1/20 0.32
BRD1 O95696 2/20 0.31
BRPF3 Q9ULD4 1/20 0.31
GPR3 P46089 1/20 0.31
LMNA P02545 1/20 0.30
SMN1; SMN2 Q16637 1/20 0.30
ERCC1 P07992 1/20 0.30
FEN1 P39748 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9312817 0.74 CA12 (0.47) BRPF1BRD4BRD9CA12CA9
SCHEMBL3482983 0.71 CASP1 (0.34) KDM4ENQO2HSD17B10GPR3MCL1
SCHEMBL5547790 0.70 BRD4 (0.39) BRPF1BRD4BRD9CA12CA9
SCHEMBL1450364 0.69 NQO2 (0.47) KDM4ENQO2ALDH1A1GPR3
SCHEMBL8557822 0.69 BRPF1 (0.50) BRPF1BRD4BRD9CA12CA9
SCHEMBL13560811 0.69 BRPF1 (0.58) BRPF1BRD4BRD9CA12CA9
SCHEMBL10445099 0.68 KDM4E (0.42) BRPF1BRD4BRD9CA12CA9
SCHEMBL3483102 0.68 MCL1 (0.60) KDM4EHSD17B10ALDH1A1CYP1A2HPGD
SCHEMBL2799169 0.67 SLC9A1 (0.43) BRPF1BRD4KDM4EHSD17B10ALDH1A1
SCHEMBL29967380 0.67 BRPF1 (1.00) BRPF1BRD4BRD9CA12CA9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8383839-B2 Heterocyclidene acetamide derivative MOCHIDA PHARMACEUTICAL CO., LTD. (JP) 2013-02-26 US disclosed
US-20110112071-A1 NOVEL HETEROCYCLIDENE ACETAMIDE DERIVATIVE MOCHIDA PHARMACEUTICAL CO., LTD. (JP) 2011-05-12 US disclosed
US-7910751-B2 Heterocyclidene acetamide derivative MOCHIDA PHARMACEUTICAL CO., LTD. (JP) 2011-03-22 US disclosed
US-20080287428-A1 Novel Heterocyclidene Acetamide Derivative MOCHIDA PHARMACEUTICAL CO.,LTD (JP) 2008-11-20 US disclosed
EP-1908753-A1 NOVEL HETEROCYCLIDENE ACETAMIDE DERIVATIVE MOCHIDA PHARMACEUTICAL CO., LTD. (JP) 2008-04-09 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080287428-A1 Novel Heterocyclidene Acetamide Derivative TRPV1, TRPV3, TRPA1 BRPF1 2857/4885BRD4 1103/4885BRD9 893/4885
US-20110112071-A1 NOVEL HETEROCYCLIDENE ACETAMIDE DERIVATIVE TRPV1, TRPV3, TRPA1 BRPF1 2857/4885BRD4 1103/4885BRD9 893/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.